BenevolentAI
we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibition of human primary cell activation ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben series reduced mouse ear in following administration of reducing expression of and ben demonstrates excellent tolerability and safety margins in enabling toxicology studies inhibition of sensory neuron activation reduction in mouse ear in | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
45 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibition of human primary cell activation ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben series reduced mouse ear in following administration of reducing expression of and ben demonstrates excellent tolerability and safety margins in enabling toxicology studies inhibition of sensory neuron activation reduction in mouse ear in | BenevolentAI
Investor Presentation
October 2022
we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibition of human primary cell activation ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben series reduced mouse ear in following administration of reducing expression of and ben demonstrates excellent tolerability and safety margins in enabling toxicology studies inhibition of sensory neuron activation reduction in mouse ear in | BenevolentAI
Investor Presentation
June 2022
we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis | BenevolentAI
SPAC
December 2021
ben is expected to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben demonstrates excellent tolerability and safety margins in enabling toxicology studies ben inhibition of human primary cell activation inhibition of sensory neuron activation | BenevolentAI
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io